The British Society for Haematology (BSH) Lymphoma Special Interest Group (SIG) primarily has an educational role. The educational events cover both the clinical aspects of lymphoma diagnosis and management, as well as basic scientific and translational science. Lymphoma research will remain the remit of the lymphoma NCRI Lymphoma Clinical Studies Group.
The group organises one educational event every year in autumn, in different geographical locations, and two business meetings per year. A second educational meeting might be held during the ASM, subject to the approval of the BSH Programme Committee.
The SIG committee has 11 elected representatives, members of the BSH, with one reserved position for each of the devolved nations. There are also co-opted members representing specialist nursing, imaging, histopathology and members in training. There are therefore a total of 17 committee members.
It is hoped that there will be even geographical representation but the elected members are all elected on the basis of votes cast without reference to their geographic location except for the reserved positions mentioned above. The Chair is chosen from within the Committee, once elected.
Members serve a three year term or less if agreed to allow a staggered rotation.
The BSH Lymphoma SIG offers advice and professional opinion to and through the External Affairs Committee when requested to do so.
Chair: Dr Sridhar Chaganti
Vice Chair: Dr Cathy Burton
For more information, email [email protected] or call 020 7713 0990.
Join the Lymphoma Special Interest Group.
The SIG welcomes both members and non-members of the BSH who have a special interest in lymphoma and it is free to join.
Please note you will need to log in or create a website account to join a SIG.
BSH Lymphoma Podcast
Dr Wendy Osborne discusses an approach to the management of patients with early, unfavourable Hodgkin's lymphoma, focusing on the current evidence, the role of positron emission tomography (PET) and the challenges faced by this subgroup of patients.
Dr Osborne is a consultant haematologist at Newcastle upon Tyne Hospitals NHS Foundation Trust. She has a specialist interest in the field of lymphoma, is a member of the National Cancer Research Institute (NCRI) clinical subgroups looking at high-grade Hodgkin's and T cell lymphomas, and is the chair of the BSH Lymphoma Special Interest Group.
Dr Rory McCulloch discusses the clinical management of mantle cell lymphoma (MCL), including indolent MCL, upfront management in younger patients, challenges of aggressive blastoid disease and how new therapies may shape future treatment algorithms.
Dr McCulloch is a consultant haematologist at Gloucestershire Hospitals NHS Foundation Trust and recently worked as a Lymphoma Clinical Research Fellow under Professor Simon Rule at Plymouth University.
He was vice-chair of the trainee-led research network HaemSTAR and is a BSH Lymphoma Special Interest Group member.
Dr Shirley D’Sa discusses the management of Waldenström macroglobulinaemia (WM).
Dr D’Sa is a haematologist and associate professor at University College London Hospitals NHS Foundation Trust (UCLH), a busy academic centre in central London, where she also completed her specialist training in haematology.
She specialises in the management of patients with Immunoglobulin M (IgM) related conditions and paraproteinaemic neuropathies.
She is the clinical lead for the UCLH Centre for WM and Related Disorders and haematological lead in the Joint Neurohaematology Service alongside the neurology lead, Professor Michael Lunn, at the National Hospital for Neurology, Queen Square, London.
Dr D’Sa is a co-trustee with patients and colleagues in the UK-registered charity, WMUK. She is the Chief Investigator for the Rory Morrison Registry project for WM and associated conditions, which has more than 1,200 patients registered from several centres across the UK. And a member of the UK Medical Advisory Panel of Lymphoma Action.
Dr D’Sa is a CI/PI in several clinical trials in WM and cold agglutinin disease (CAD) and is a committee member of the International Workshops on WM and the BSH Guidelines group.
She is a supervisor to successive research fellows in the field of Waldenström and paraproteinaemic neuropathies, as well as haematology specialist trainees and undergraduates at the University College London (UCL) Medical School.
Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options.
He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients.
Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham.
His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematologic malignancies, lymphomas and stem cell transplantation.
Dr Matthew Ahearne is a consultant haematologist at University Hospitals of Leicester NHS Trust. His main clinical and research focus is on T-cell lymphomas.
Dr Ahearne is Deputy Chair of the National Cancer Research Institute (NCRI) T-cell lymphoma working group and an NCRI Lymphoma Science sub-group member.
Dr Duncan Murray discusses mycosis fungoides and sezary syndrome.
Dr Murray completed his PhD at the University of Birmingham, looking at the interaction between the immune system and malignant T cells in skin lymphoma.
He finds the interaction between a "good" and "bad" T cell fascinating. He has used multiple single-cell laboratory techniques to tease apart the two populations (including V-beta antibodies, single-cell T-cell receptor (TCR) and ribonucleic acid (RNA) sequencing and mass cytometry).
Skin lymphoma is an unusual disease in that key determinants of the patient's outcome sit very close together. Both anatomically and in phenotype. His current work focuses on what we can learn from high-dimensional single-cell data and the bioinformatic process to assist this.
Dr Nikesh (Nik) Chavda discusses supportive care in lymphoma.
Dr Chavda is a haematology consultant at University Hospitals Bristol and Weston, with an interest in B-cell malignancies, cellular therapies and histiocytic disorders.
Dr Sridhar Chaganti discusses the use of bispecific T-cell engagers (BITE’s) in large B-cell lymphoma.
Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham.
His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematological malignancies, lymphomas, stem cell transplantation and cellular therapies.